Nuwellis decoration

News Release

Nuwellis, Inc. Announces 35 Percent Increase in Revenue for Second Quarter 2021 Over Previous Year and Provides Company Update

August 10, 2021

EDEN PRAIRIE, Minn., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) announced today its results for the second quarter ended June 30, 2021, which included the following highlights:

  • Reported record quarterly revenue of $2.5 million, a 35 percent increase compared to the prior year period
  • Realized strong sequential growth across all customer markets and recorded the sixth consecutive quarter with double-digit revenue growth vs. prior year
  • Welcomed George Montague, former CFO and COO of Smiths Medical, as new CFO
  • Welcomed Neil Ayotte, a 16-year veteran of Medtronic plc and most recently EVP & General Counsel of Bluestem Group, as Senior VP, General Counsel, Secretary and Chief Compliance Officer
  • Received Category III CPT code for the use of therapeutic ultrafiltration, effective January 1, 2022
  • Announced a three-year national purchase agreement with Premier, Inc., one of the nation’s largest group purchasing organizations
  • Ended the quarter with $24.0 million in cash and no debt

“I am proud to report that Nuwellis achieved record quarterly revenues for the second quarter 2021 with strong sequential growth across all segments,” said Nestor Jaramillo, CEO of Nuwellis. “We continue to execute and deliver on key strategic initiatives that produce impressive double-digit growth rates seen over the past six quarters. With the recent addition of a CPT code for treating patients suffering from fluid overload, we believe we are positioned to continue to accelerate the growth of our business in the future.”

Second Quarter 2021 Financial Results
Revenue for the second quarter of 2021 was $2.5 million, an increase of 35% compared to $1.9 million in the prior year period. Revenue growth in the second quarter of 2021 was driven by both increased capital equipment sales and strong utilization of disposables.

  • Critical Care continued its strong momentum, driven by increased utilization and unit placements at hospitals in the ICU setting across the country. With COVID-related hospitalizations in the U.S. having significantly declined since the vaccine rollout, increased utilization among non-COVID critically ill patients remains a durable growth trend.
  • Pediatric revenue delivered strong double-digit sequential revenue growth for the second straight quarter primarily due to increased penetration and utilization at established accounts, in addition to console sales to new customers.
  • Heart Failure revenue increased sequentially due to more normalized patient behavior and increased access to hospitals as COVID-19 infection rates decline.

Gross margin was 60.2% for the second quarter 2021, compared to 64.4% in the prior year period. The decline in gross margins was primarily due to a production ramp last year to support the launch of the Aquadex SmartFlow system and to meet expected future demand. Gross margins should benefit in future periods as production volumes increase and fixed overhead get allocated over a larger base.

Selling, general and administrative (“SG&A”) expenses for the second quarter of 2021 were $5.1 million, an increase of 20% compared to the prior year period. The increase in SG&A was primarily due to our continued investment in sales and marketing activities, along with nonrecurring leadership transition costs. Research and development (“R&D”) expenses in the second quarter of 2021 were $1.2 million, an increase of 33% compared to the prior year period. The increase in R&D expenses was driven primarily by investments in new products and clinical support of our pediatric registry.

The net loss for the second quarter of 2021 was $4.7 million, compared to a net loss of $3.9 million in the prior year period.

Cash and cash equivalents were approximately $24.0 million with no debt as of June 30, 2021. During the second quarter of 2021, the Company used $3.9 million of cash from operations.

2021 Full-Year Outlook
The Company expects quarterly revenue to continue increasing sequentially for the remainder of 2021 as it continues to build its commercial presence and seeks to increase utilization of Aquadex therapy. This outlook includes several assumptions, including no significant change in utilization or procedure volumes associated with COVID-19 resurgences.

Webcast and Conference Call Information
The Company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the Company’s performance. To access the live webcast, please visit Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following the call at

About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minn., with a wholly-owned subsidiary in Ireland.

About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2021 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercialization strategy, the impact of the COVID-19 pandemic, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited, in thousands, except per share amounts)

    Three months ended
June 30,
Six months ended
June 30,
    2021   2020     2021 2020  
Net sales $ 2,508   $ 1,863   $ 4,426   $ 3,493  
Cost of goods sold   997     664     1,949     1,460  
Gross profit   1,511     1,199     2,477     2,033  
Operating expenses:                        
Selling, general and administrative   5,063     4,234     10,300     8,770  
Research and development   1,174     885     2,121     1,749  
Total operating expenses   6,237     5,119     12,421     10,519  
Loss from operations   (4,726 )   (3,920 )   (9,944 )   (8,486 )
Other income (expense), net   (2 )       (3 )    
Loss before income taxes   (4,728 )   (3,920 )   (9,947 )   (8,486 )
Income tax expense   (3 )   (2 )   (5 )   (4 )
Net loss $ (4,731 ) $ (3,922 ) $ (9,952 ) $ (8,490 )
Basic and diluted loss per share $ (0.72 ) $ (3.10 ) $ (2.04 ) $ (11.31 )
Weighted average shares outstanding – basic and diluted   6,532     1,264     4,887     906  
Other comprehensive loss:                        
Foreign currency translation adjustments $   $ (2 ) $ (3 ) $ (5 )
Total comprehensive loss $ (4,731 ) $ (3,924 ) $ (9,955 ) $ (8,495 )


Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)

    June 30,
    December 31,
ASSETS   (unaudited)        
Current assets            
Cash and cash equivalents          $ 23,978     $ 14,437    
Accounts receivable   1,177       905    
Inventories   2,656       2,957    
Other current assets   413       237    
Total current assets   28,224       18,536    
Property, plant and equipment, net   1,260       1,200    
Operating lease right-of-use asset   156
Other assets         21    
TOTAL ASSETS $ 29,640     $ 20,012    
Current liabilities            
Accounts payable $ 1,787     $ 1,097    
Accrued compensation   1,577       2,192    
Current portion of operating lease liability   160       206    
Current portion of finance lease liability   25       24    
Other current liabilities   54       66    
Total current liabilities   3,603       3,585    
Operating lease liability         55    
Finance lease liability   41       54    
Total liabilities   3,644       3,694    
Commitments and contingencies                                           
Stockholders’ equity            
Series A junior participating preferred stock as of June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 30,000 shares, none outstanding            
Series F convertible preferred stock as of both June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares            
Preferred stock as of both June 30, 2021 and December 31, 2020, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding            
Common stock as of June 30, 2021 and December 31, 2020, par value
$0.0001 per share; authorized 100,000,000 shares, issued and outstanding 6,532,018 and 2,736,060, respectively
Additional paid-in capital   269,296       249,663    
Accumulated other comprehensive loss:            
Foreign currency translation adjustment   (10 )     (7 )  
Accumulated deficit   (243,290     (233,338 )  
Total stockholders’ equity   25,996       16,318    


Condensed Consolidated Statements of Cash Flows
(unaudited, in thousands)

    Six months ended
June 30,
Operating Activities:            
Net loss $ (9,952 ) $ (8,490 )
Adjustments to reconcile net loss to cash flows used in operating activities:            
Depreciation and amortization   256     151  
       Stock-based compensation expense, net   736     727  
       Loss on disposal of property and equipment       46  
Changes in operating assets and liabilities:            
Accounts receivable   (272 )   (179 )
Inventory   122     (1,104 )
Other current assets   (176 )   20  
Other assets and liabilities   9     112  
Accounts payable and accrued expenses   75     (43 )
Net cash used in operating activities   (9,202 )   (8,760 )
Investing Activities:            
Purchases of property and equipment   (137 )   (69 )
Net cash used in investing activities   (137 )   (69 )
Financing Activities:            
     Proceeds from public stock offerings, net   18,896     13,040  
     Proceeds from warrant exercises   1     2,340  
     Payments on finance lease liability   (14 )   (4 )
Net cash provided by financing activities   18,883     15,376  
Effect of exchange rate changes on cash   (3 )   (5 )
Net increase in cash and cash equivalents   9,541     6,542  
Cash and cash equivalents - beginning of period   14,437     1,279  
Cash and cash equivalents - end of period $ 23,978   $ 7,821  
Supplemental cash flow information            
Inventory transferred to property, plant and equipment $ 179   $ 112  
Equipment acquired through finance lease liability $   $ 67  


George Montague
Chief Financial Officer, Nuwellis, Inc.

Matt Bacso
Gilmartin Group        

Jessica Stebing

Primary Logo

Source: Nuwellis, Inc.